Zacks Research Issues Positive Outlook for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities researchers at Zacks Research boosted their Q4 2025 EPS estimates for shares of Halozyme Therapeutics in a note issued to investors on Wednesday, January 28th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings of $1.77 per share for the quarter, up from their previous forecast of $1.76. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q2 2026 earnings at $1.49 EPS, Q4 2026 earnings at $1.84 EPS and Q3 2027 earnings at $2.02 EPS.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. The company had revenue of $354.26 million during the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The firm’s revenue for the quarter was up 22.1% on a year-over-year basis. During the same period in the prior year, the company posted $1.27 EPS.

Other analysts have also recently issued reports about the stock. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Leerink Partners upgraded shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 target price on the stock in a research note on Tuesday, October 14th. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. TD Cowen boosted their price objective on Halozyme Therapeutics from $79.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $78.80.

Halozyme Therapeutics Price Performance

HALO stock opened at $71.71 on Friday. The stock’s 50 day moving average is $68.93 and its two-hundred day moving average is $68.45. Halozyme Therapeutics has a 52-week low of $47.50 and a 52-week high of $79.50. The company has a market capitalization of $8.43 billion, a PE ratio of 15.10, a P/E/G ratio of 0.32 and a beta of 0.94. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59.

Insider Buying and Selling

In related news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $69.13, for a total value of $1,382,600.00. Following the sale, the chief executive officer owned 733,719 shares of the company’s stock, valued at approximately $50,721,994.47. This trade represents a 2.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $68.48, for a total value of $136,960.00. Following the transaction, the director owned 42,952 shares of the company’s stock, valued at $2,941,352.96. This represents a 4.45% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 41,398 shares of company stock valued at $2,861,352. 2.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Root Financial Partners LLC acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth about $25,000. Larson Financial Group LLC increased its stake in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 343 shares during the period. Richardson Financial Services Inc. raised its holdings in shares of Halozyme Therapeutics by 87.6% during the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 198 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $32,000. Finally, Employees Retirement System of Texas acquired a new position in shares of Halozyme Therapeutics during the second quarter worth approximately $34,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Preliminary 2025 results beat expectations and management raised 2026 outlook — the upbeat update helped push shares higher on Jan. 29 as revenue and profitability momentum improved, supporting the company’s longer‑term earnings trajectory. HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
• Positive Sentiment: Halozyme announced an acquisition of Surf Bio for up to $400M — this expands its pipeline/technology footprint tied to the ENHANZE platform and is a strategic revenue/pipeline bolt‑on that can accelerate growth if integrations and deal economics play out as expected. Halozyme Acquires Surf Bio for up to $400M
• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and kept a $90 price target — a prominent sell‑side endorsement that supports upside vs. current levels and highlights confidence in the ENHANZE platform’s commercial contribution. H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating
• Positive Sentiment: Market commentary highlights HALO as a momentum name based on style scores and recent earnings/guidance — this can attract momentum and quant flows. Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
• Neutral Sentiment: A valuation/markets piece examines whether HALO still offers value after multi‑year gains — useful context for longer‑term investors weighing current price vs. growth expectations. Is Halozyme Therapeutics (HALO) Offering Value After Strong Multi‑Year Share Price Gains
• Negative Sentiment: Zacks Research issued minor downward tweaks to several near‑term quarterly EPS estimates and kept a “Hold” stance — small cuts to Q2 2026 and Q3 2027 forecasts (and only tiny upward tweaks to other quarters) may have trimmed near‑term sentiment and contributed to selling/profit taking. (Zacks updates consolidated from analyst notes.)

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.